Acquisiton supports TQ Therapeutics’ development of ultra-short extracorporeal cell and gene therapy platorm
Martinsried, Germany, 28th May 2025 – TQ Therapeutics GmbH (“TQx”), a biotechnology
company dedicated to advancing the field of cellular therapies through innovative
technologies, today announced the acquisition of Juno Therapeutics GmbH (“Juno
GmbH”), a cell therapy company, through a share purchase agreement. Juno GmbH is a
German subsidiary of Juno Therapeutics, Inc., which is a wholly owned subsidiary of the
global biopharmaceutical company, Bristol Myers Squibb. The financial terms of the
agreement were not disclosed.
TQx is transforming the traditional production of cell therapies towards a decentralized,
scalable, fast and highly automated cost-ePicient platform. The acquisition of Juno
GmbH will increase TQx’s capabilities, expanding access to intellectual property and
license agreements that will support the development of the company’s potentially
transformative cell processing platform.
“This acquisition presents an incredible opportunity for us to continue development of
our breakthrough ultra-short extracorporeal cell and gene therapy approach to create
treatments of the future,” said Dr. Christian Eckert, CEO of TQx. “This strategic transaction
reinforces our commitment to making cell and gene therapy broadly accessible to
address the medical needs of many patients.”
About TQ Therapeutics GmbH: TQ Therapeutics is a biotechnology company dedicated
to advancing the field of cellular therapies through innovative technologies. The
company’s mission is to develop a transformative cell processing platform, enabling
advanced and aPordable treatments in CGT. This technology will deliver highly
individualized cell therapies directly to the patient’s bed-side.
Contact
TQ Therapeutics GmbH
Christin Zündorf
Email: info@tqtherapeutics.com
Web: www.tqtherapeu,cs.com
LinkedIn: h8ps://www.linkedin.com/company/tq-therapeu,cs